Haleon plc Cash Flow Conversion Efficiency
Haleon plc cash flow conversion efficiency. Based on the latest financial reports, Haleon plc (HLN) has a cash flow conversion efficiency ratio of 0.055x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($902.61 Million) by net assets ($16.34 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Haleon plc (2019–2025)
Cash flow conversion efficiency of Haleon plc from 2019 to 2025. This chart illustrates how Haleon plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Haleon plc (HLN) stock price for real-time trading data and today's change.
Haleon plc Cash Flow Conversion Ratio Explained
Haleon plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Haleon plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Haleon plc ranked by their cash flow conversion efficiency. Also see market value of Haleon plc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD
|
-0.149x |
|
Ameriprise Financial Inc
NYSE:AMP
|
0.074x |
|
Itaú Unibanco Holding S.A
F:BVXB
|
-0.202x |
|
Goodman Group
AU:GMG
|
0.053x |
|
AngloGold Ashanti Ltd
JSE:ANG
|
0.133x |
|
Bank of Communications Co. Ltd
F:C4C
|
0.092x |
|
CSL LTD SPON.ADR 2
F:CSJA
|
N/A |
|
JD.com Inc Adr
NASDAQ:JD
|
0.132x |
Annual Cash Flow Conversion Efficiency for Haleon plc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Haleon plc from 2019 to 2025. Review HLN cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.46 Billion | $2.29 Billion | 0.139x | -2.06% |
| 2024-12-31 | $16.22 Billion | $2.30 Billion | 0.142x | +12.98% |
| 2023-12-31 | $16.73 Billion | $2.10 Billion | 0.126x | +0.14% |
| 2022-12-31 | $16.46 Billion | $2.06 Billion | 0.125x | +144.80% |
| 2021-12-31 | $26.48 Billion | $1.36 Billion | 0.051x | -4.56% |
| 2020-12-31 | $26.22 Billion | $1.41 Billion | 0.054x | +87.12% |
| 2019-12-31 | $27.41 Billion | $786.00 Million | 0.029x | -- |
About Haleon plc
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; an… Read more